These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30452015)

  • 1. Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force".
    Mahon SM; Nagtalon Cutrone J; Baron RH
    Clin J Oncol Nurs; 2018 Dec; 22(6):610. PubMed ID: 30452015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.
    Skop M; Lorentz J; Jassi M; Vesprini D; Einstein G
    Am J Mens Health; 2018 Jul; 12(4):961-972. PubMed ID: 29400121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
    Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
    Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Fostira F; Saloustros E; Apostolou P; Vagena A; Kalfakakou D; Mauri D; Tryfonopoulos D; Georgoulias V; Yannoukakos D; Fountzilas G; Konstantopoulou I
    Breast Cancer Res Treat; 2018 May; 169(1):105-113. PubMed ID: 29335925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
    Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
    Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
    Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breast cancer in male].
    Würstlein R; Hesse A; König A; Schulte-Vorwick F; Schrodi S; Ditsch N; Mahner S; Harbeck N
    MMW Fortschr Med; 2017 Dec; 159(21-22):67-72. PubMed ID: 29230744
    [No Abstract]   [Full Text] [Related]  

  • 11. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
    Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
    J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1/2 mutation analysis in male breast cancer families from North West England.
    Evans DG; Bulman M; Young K; Howard E; Bayliss S; Wallace A; Lalloo F
    Fam Cancer; 2008; 7(2):113-7. PubMed ID: 17636422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer.
    Singer CF; Rappaport-Fuerhauser C; Sopik V; Narod SA
    Clin Genet; 2015 Aug; 88(2):187-9. PubMed ID: 25112434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.
    Coppa A; Buffone A; Capalbo C; Nicolussi A; D'Inzeo S; Belardinilli F; Colicchia V; Petroni M; Granato T; Midulla C; Zani M; Ferraro S; Screpanti I; Gulino A; Giannini G
    Breast Cancer Res Treat; 2014 Dec; 148(3):629-35. PubMed ID: 25395318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
    Torres D; Bermejo JL; Rashid MU; Briceño I; Gil F; Beltran A; Ariza V; Hamann U
    Sci Rep; 2017 Jul; 7(1):4713. PubMed ID: 28680148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of breast cancer in male BRCA2 carriers.
    Evans DG; Susnerwala I; Dawson J; Woodward E; Maher ER; Lalloo F
    J Med Genet; 2010 Oct; 47(10):710-1. PubMed ID: 20587410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.